Joel Buxbaum, MD | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Researchers
Joel Buxbaum, MD

Joel Buxbaum, MD

Researcher
Professor of Molecular Medicine Emeritus
Department of Molecular and Experimental Medicine
The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, California, United States
Joel Buxbaum, MD is a Professor of molecular medicine emeritus at The Scripps Research Institute and Consulting Chief Medical Officer at Protego Biopharma, La Jolla, California, United States. Dr. Buxbaum earned his M.D degree from Tufts University and trained clinically at the University of Utah Affiliated Hospitals after which he was a research associate at NIH. He did post-doctoral training at New York University (Immunology) and the Albert Einstein College of Medicine (Cell Biology).
 
He was an American Cancer Society Faculty Fellow in Cancer Research at the California Institute of Technology.  He was elected to the American Society for Clinical Investigation and the Association of American Physicians. Until 1999 he was Professor of Medicine at New York University School of Medicine.  From 1999 until 2017 he was Professor of Molecular Medicine at the Scripps Research Institute.  
 
He currently also holds a research appointment at the Scintillon Institute, San Diego, California and has been and continues to be a consultant for pharmaceutical companies developing new therapies for ATTR.

 
 
 
 
view profile

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close